BY MARKETWIRE
-
Novo Nordisk working on response after FDA letter about misleading Wegovy ad
Novo Nordisk is functioning to abide by the United States health and wellness authorities.
-
Danske Bank: Bavarian Nordic could reveal cost-saving measures in upcoming annual report
” We are progressively persuaded that Bavarian Nordic will certainly reduce the decrease by executing cost-saving steps,” the expert states.
-
Analyst: Coloplast’s Kerecis woes may mean downgrade
Kerecis, that makes injury treatment items from fish skin, was influenced by unpredictability in the United States throughout the quarter.
-
Coloplast’s CEO welcomes strong growth in urology – acquisitions to support development
In the very first quarter, Coloplast obtained the United States medtech firm Uromedica.
-
Novo Nordisk CEO on new price pressure risk: We have economies of scale
With substantial cost decreases, Novo Nordisk wishes to recover a few of the clients shed to compounders.
-
Lundbeck CEO predicts results for migraine candidate as next major catalyst
Lundbeck’s chief executive officer Charl van Zyl is especially hopeful in the short-term regarding the outcomes of a migraine prospect that Lundbeck is examining in a stage I…
-
Boston Scientific disappoints with low forecast for 2026
The United States medtech firm stopped working to satisfy market assumptions with its fourth-quarter monetary outcomes.
-
GN takes a beating during teleconference with analysts
GN’s target rate reduced by DNB Carnegie after economic outcomes.
-
Hims & Hers will sell copies of the Wegovy pill for USD 49
This is a significant price cut when contrasted to Novo Nordisk’s initial cost of USD 149 each month.
-
Analysts expect a subdued start to the year for Coloplast: Challenges in China will continue to weigh heavily
On the various other hand, high development in the United States and bigger orders in arising markets are anticipated to sustain the ostomy department.
